Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management
30/08/2026 11:18
BRIEF-Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management Aug 30 (Reuters) - Ascletis Pharma Inc. 1672.HK:
ASCLETIS ANNOUNCES FIRST PARTICIPANT DOSED IN A GLOBAL PHASE III CLINICAL PROGRAM OF ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ASC30 FOR CHRONIC WEIGHT MANAGEMENT
ASCLETIS PHARMA - TOPLINE PHASE III DATA EXPECTED Q3 2028; FDA NDA BY END 2028; EMA MAA EARLY 2029
Source text: ID:nPn1HvWqka
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management